| TTM
|
12/31/2025
|
12/31/2024
|
|
|---|---|---|---|
| Total Revenue
|
33,302 | 51,174 | 27,413 |
| Selling, General and Administrative Expenses
|
-12,961 | -16,449 | -13,163 |
|
Research and Development Expenses
|
-51,047 | -60,795 | -57,079 |
|
Operating Income/Expenses
|
-64,008 | -77,244 | -70,242 |
|
Total Operating Profit/Loss
|
-30,706 | -26,070 | -42,829 |
| Total Net Finance Income/Expense
|
209 | 933 | 3,773 |
|
Other Income/Expense, Non-Operating
|
-2,141 | 1,527 | 1,495 |
|
Non-Operating Income/Expenses, Total
|
-1,932 | 2,460 | 5,268 |
|
Pretax Income
|
-32,638 | -23,610 | -37,561 |
|
Provision for Income Tax
|
334 | 1,802 | -10,225 |
|
Net Income from Continuing Operations
|
-32,304 | -21,808 | -47,786 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-32,304 | -21,808 | -47,786 |
|
Net Income after Non-Controlling/Minority Interests
|
-32,304 | -21,808 | -47,786 |
|
Net Income Available to Common Stockholders
|
-32,304 | -21,808 | -47,786 |
|
Diluted Net Income Available to Common Stockholders
|
-32,304 | -21,808 | -47,786 |
| Basic EPS
|
-3.84 | -2.60 | -5.67 |
| Diluted EPS
|
-3.84 | -2.60 | -5.67 |
|
Basic Weighted Average Shares Outstanding
|
8,399.30 | 8,399.30 | 8,430.92 |
|
Diluted Weighted Average Shares Outstanding
|
8,399.30 | 8,399.30 | 8,430.92 |
| Income Statement, Supplemental
|
|||
|
EBIT
|
-32,847 | -24,543 | -41,334 |
|
EBITDA
|
-29,910 | -21,466 | -38,445 |
|
Normalized EBITDA
|
-22,770 | -18,843 | -36,969 |
|
Normalized Income
|
-25,237.06 | -19,385.40 | -46,619.96 |
|
Total Unusual Items
|
7,140 | 2,623 | 1,476 |
|
Total Unusual Items Excluding Goodwill
|
7,140 | 2,623 | 1,476 |
|
Tax Effect of Unusual Items
|
73.06 | 200.40 | 309.96 |
|
Tax Rate, Calculated
|
0.01 | 0.08 | 0.21 |
12/31/2024 - 7/27/2026
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade